Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532340 | 0.84 | GRM5 (0.50) | GRM5 | |
| SCHEMBL1644168 | 0.84 | GRM5 (0.50) | GRM5 | |
| SCHEMBL531357 | 0.84 | GRM5 (0.50) | GRM5 | |
| SCHEMBL1643910 | 0.84 | GRM5 (0.50) | GRM5 | |
| SCHEMBL7654253 | 0.83 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL7655582 | 0.83 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL10242113 | 0.83 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL7654264 | 0.83 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL10242859 | 0.79 | GRM5 (0.43) | GRM5PGRKCNH2 | |
| SCHEMBL1529100 | 0.79 | GRM5 (0.39) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | GRM5 4799/4885PGR 995/4885KCNH2 2563/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | GRM5 4799/4885PGR 995/4885KCNH2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.